Common questions researchers ask about tesamorelin — laboratory context only.
What structural feature defines tesamorelin?
An N-terminal modification (a trans-3-hexenoic acid group) added to the GHRH-fragment backbone, which is reported to confer resistance to the enzyme primarily responsible for degrading unmodified GHRH analogs — detailed in its mechanism of action.
How does tesamorelin's stability compare to sermorelin?
Tesamorelin's modification specifically targets enzymatic degradation resistance, giving it a longer research half-life than the unmodified sermorelin fragment, though both act on the same GHRH receptor.
Is tesamorelin structurally related to CJC-1295?
Both are modified GHRH-fragment analogs but use different stabilization chemistry — CJC-1295 variants use albumin-binding (DAC) or backbone substitutions, while tesamorelin uses its distinct N-terminal group; see the chemistry article for specifics.
How is it supplied and handled?
Lyophilized powder, kept cold and dark; general handling is in reconstitution and storage.
What documentation should accompany a lot?
A lot-specific certificate of analysis with HPLC purity and mass-spec identity — see how to read a CoA.
Product page: Tesamorelin research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.